Combination of erlotinib and naproxen employing pulsatile or intermittent dosing profoundly inhibits urinary bladder cancers

Daily dosing of either non-steroidal anti-inflammatory drugs (NSAIDs) or EGFR inhibitors has been shown to prevent bladder cancer development in a N-butyl-(4-hydroxybutyl)nitrosamine (OH-BBN) induced rat model. However, these inhibitors cause gastrointestinal ulceration and acneiform rash, respectiv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Prev Res (Phila)
Main Authors: Mohammed, Altaf, Miller, Mark Steven, Lubet, Ronald A., Suen, Chen S., Sei, Shizuko, Shoemaker, Robert H., Juliana, Margaret M., Moeinpour, Fariba L, Grubbs, Clinton J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7060101/
https://ncbi.nlm.nih.gov/pubmed/31818850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-19-0339
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados